We are bombarded with marketing messages every day, at every turn. These messages are carefully crafted, meticulously tested, and precisely delivered in order to maximize their influence on our perception and behavior. Most of the time consumers don’t stand a chance against marketers. There is great asymmetry in the information available to these two classes. […]Read more "If Werner Heisenberg Could See Us Now…"
Looks like HIStalk picked up my recent post on Epic over the weekend. I’ve been an avid reader of Mr. H since 2004, so to say I’m excited about the mention would be an understatement. To all the folks clicking through, please feel free to weigh in with a comment or even subscribe! Mr. H […]Read more "Picked up by HIStalk"
Mr. H posted the following yesterday: From Barry: “Re: Epic. A market research report suggests that Epic is backing off its push for inpatient installations and going with an ambulatory-only sales approach to plant the seed for future inpatient sales.” That was reported by two consultants quoted in the report, with an additional consultant saying […]Read more "Why Epic Might Refocus on the Ambulatory EMR Market"
I have noticed that much of the last few days’ search traffic to this site clusters around themes related to the recent HSG/GE Healthcare JV, the accompanying HSG layoff, wondering what will happen to the customers, etc. In an attempt to stay true to my roots as a marketer, here’s an attempt to give my readers what […]Read more "HSG Layoffs, Musings on NewCo Culture"
It’s been two and a half years since McKesson executed a major shuffle of the executive suite in its Technology Solutions business, and we’ve now seen what I’d consider to be the first major announcement since that change: The company is halting development on its Horizon inpatient clinical and revenue cycle products and doubling down […]Read more "McGuessin’: The McKesson Strategy Guessing Game"
I was happy to see today’s HIStalk interview with Michael Weintraub, CEO of Humedica. This is a company that seems to have an innovative product coupled with an innovative business model that is positioned for greatness as health reform kicks into high gear. Humedica’s offering has a value proposition is similar to that of analytics offerings from […]Read more "Thoughts on Humedica"
A recent post by Ezra Klein of The Washington Post seems to call into question the utility of preventative measures as compared with treatment of advanced disease states. Klein quotes a book called “Prevention vs. Treatment” edited by Haley Faust and Paul Menzel, specifically a chapter written by Louise Russell who in turn “draws heavily […]Read more "Prevention vs. Treatment?"
Yesterday’s post by Sean Nolan, Microsoft’s Distinguished Engineer who runs R&D for the Health Solutions Group, seems to affirm the conjecture that HealthVault will provide a means for Microsoft to retain key technical talent as it forms a joint venture with GE Healthcare: At the end of the day — I want to assure you that […]Read more "Who’s in your lifeboat?"
Today Microsoft and GE announced a new joint venture that combines Microsoft’s Amalga, Vergence, and ExpreSSO products with GE’s Qualibria and eHealth offerings in a new company to be named later. GE’s Michael J. Simpson will be CEO of the new company, and Peter Neupert has announced his retirement from Microsoft. I’m not surprised by the […]Read more "Thoughts on today’s Microsoft/GE Healthcare joint-venture announcement"
(Originally published 3/21/2007 on zachmortensen.net) The term moral hazard is generally used within the insurance industry to describe the tendency of the insured to increase their risk tolerance once their risks are hedged by insurance. For example, a consumer with a homeowner’s insurance policy might decide against returning home to double-check that she had turned […]Read more "Moral Hazard in Healthcare IT"